Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Its there now.
That's odd. Don't have a clue. However, would have been more interesting if he bought <$10k instead of $1560. Is it just me, or out of all the mj stock tickers, only cann seems to have added employees to their company. Most that I see have a few employees and hardly ever update their profile like cann does.
Updated post. Thanks.
I'm going to take a shot in the dark and in my opinion when this trades again in now 9 days it will be down about 70%, so .00162 at the open. I hope for you all I'm wrong. Cann was trading around $30 and after the 10 day suspension was at $7 and went to $20 before closing a little lower for the first day on the greys. These aren't exact prices but close to it. I don't think what happen to cann will happen to fitx. Fitx was a scam. Cann is now off the grey's and trying to grow a business. Again, sorry you all have to go thru this, but trade wisely. Nobody really knows what will happen at the open, but it doesn't look good, IMHO. Will be watching this one the following friday.
I was able to buy, but did not try to sell any phot with e*trade while on the Gray's.
Just to clarify things. When I mention our brothers and sisters at fitx, I was not comparing the companies. Fitx is nothing compared to Cann. I just meant our fellow stock traders in general.
Was not trying to make a comparison, I totally agree with you. Growlife is a company, compared to fitx that is nothing but fluff. I just meant our fellow stock traders in general. We all have a purpose to make money. Some of us here remember that day when our hearts sank.
Cann has always been my number one pic for the industry where in. Yes it hurt when this company got suspended because of one investor. Have been waiting a long time for this stock to come around again, and I hope it does soon. I have watched some of you post on this board and I believe some of you are as passionate about this company as I. I to believe that buying at less than a dollar is a steal and in time I hope that proves right. The company has been increasing its revenue each quarter last year, some of you might know this simply by looking at news on their website under the investor relations relating to the January 6, 2016 Presentation. Will be interesting to see what the year ending financials look like and any update as to how this company is progressing would be nice. According to the otcshort report Friday the 19th, only 3.66% of the stock was shorted, compared to an average of 35% or higher for the past month. I'm hoping that the money managers are done shorting and we start a move forward. Sooner or later news will come. Don't blame them for taking it slow after what happened just about two years ago, but dam. On another note, our brother and sisters at phot are in glory, however they had to wait longer than us to get off the greys. Would have been nice to get the support they got when cann came off the greys, but then again maybe where buying really cheap shares here. And on a sad note our brother and sisters at fitx are singing the blues as of this morning. GLTA here.
These past two days it has been nice to see phot back, but our brothers and sisters at fitx are now living the blues we once lived here.
Ooohhhh. Now that's interesting. Did not know. Thanks. I've got some dd to do.
Cann got halted first, phot about a week later, and fspm a few weeks after that. Good luck with fitx.
This stock will be halted for 10 business days. After that it will trade without a bid or an ask. Eventually, you will find that some brokers will not let you buy if you wish to in a few days once it resumes trading. E*trade will. I'm not promoting the company, but it was one that let me accomplish what I needed. Nice to see that someone is able to post what we all remember about this company a little over a year ago. Thanks for the memories.
I see grey crossbones on the otcmarket website, call it what you want suspended, halted either way its going to stink for anyone holding.
So glad I left this stock back when Bill C. wouldn't open the barn doors and the town was in an uproar. I noticed someone mentioned phot a few messages back. It took until two days ago after the market closed that news was breaking on phot that it would be trading off the greys in the morning, that being yesterday from almost 2 years ago. Cann came back I think just over a year, but there story was just about one investor that sold restricted shares. Sorry for anyone who was still here with money on the table. With what I watched phot & cann go thru to get back trading again, in my honest opinion it's going to be a long, long time before if ever it trades off the greys. Just a heads up, you can not short the stock when its in the greys. I was able to buy phot stock on the greys through E*trade just in case someone ACTUALLY wants to buy more fitx. I personally will not touch this stock again. Again, sorry for anyone who lost money here. I took the advice from someone on this board a while back that this could one day happen. It sucks. I was holding cann, phot and fspm and all three got halted, I feel lucky 2 of the 3 are back trading again and maybe one day I can regain my loses.
And it's only day one. How long before others realize phot is coming back? Next week could be real exciting, but knowing my luck only the flippers will be making money.
Cann was halted just prior to phot, and then fspm was halted. I was holding all 3 when the sec went on it's mj rampage. Cann was back trading in about one year. However, what got each one halted are two totally different situations. Glad to see two of the three coming back. IMO, I want this stock to start climbing, right now I don't break even until .19, but is the company worth 14.5 million? as of Feb. 17th. Always wish everyone the best, and maybe in a few years we can all look back at this day and say, I'm so glad I held my shares.
Just heard from Trump, it's HUGE.
I'm tired of waiting. Wishing this would start moving.
Cann launched from just under $1 to over 8.50 after they won their lawsuit against the shareholder that sold his restricted shares that put them on the grays. However, it retracted since then.
I usually don't post links because they're at the top of the page. Didn't think it would take you long to find it.
NEWS IS OUT!!!! This could be the news we needed. Good things to come.
As usual, I am wrong. Maybe some positive news one day soon will get this moving again.
Not sure if this is any indication of whats to come, but I do find it very interesting. In February of last year I jumped into this company during the spike. I just looked backed at the chart on Feb. 20th and the stock dropped from 1.63 to 1.45 on Friday. Monday it took off. Could history repeat itself? The set-up here looks identical including the volume of 500k. We'll see Monday. Good Luck.
I was here. Remembering like it was yesterday. Was playing with money made from another stock.
Hope this is just an indication of whats to come. After hours showing $2.18, hoping its real. Wishing everyone watching the best in 2016. Maybe someone who trades daily can shed some light on what triggered this. Not really believing, unless it opens tomorrow morning at $2.18.
Buy volume was 192k. Best wishes to everyone here in 2016. Others will be showing up soon.
Well I just bought some more and I see I'm not the only one. Glad to see some movement.
Any ideas as to why this isn't trading yet today? I might buy more just to see at least one trade.
Because nobody takes the time. They see a big percentage gain and assume the stock must be good, because everyone else is buying it. Next couple months is the time to be in marijuana stocks and they year hasn't even started and some already flipped this. Come February and if we are still at .02 I'll be shocked. GLTA
Well here's some interesting news for anyone watching.
Biocept Announces $15 Million Common Stock Purchase Agreement with Aspire Capital Fund
SAN DIEGO, Dec. 22, 2015 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC) ("Biocept" or the "Company"), a molecular diagnostics company commercializing and developing blood-based liquid biopsies to improve the detection, monitoring and treatment of cancer, announces a $15 million common stock purchase agreement with Aspire Capital Fund, LLC ("Aspire"), a Chicago-based institutional investor. Upon entering into the agreement, Aspire purchased $1 million of Biocept's common stock at $1.60 per share, representing an 8.1% premium over the closing price of $1.48 on December 21, 2015.
http://photos.prnewswire.com/prnvar/20151013/276540LOGO
Proceeds from the agreement will be used to fund Biocept's general corporate purposes, including research, development and commercialization activities.
After a registration statement related to the transaction has been filed and declared effective by the U.S. Securities and Exchange Commission (SEC), Biocept, at its sole discretion, will have the right to sell common stock to Aspire over a 30-month period at prices based on prevailing market prices at the time of each sale. By controlling the timing of each sale, Biocept may efficiently raise capital to advance its operations while effectively minimizing the dilution of its existing shareholders.
"This agreement affords us added balance sheet strength and flexibility as we further expand our menu of commercial assays and continue to drive physician adoption," said Michael W. Nall, President and CEO of Biocept. "We are dedicated to providing reliable and actionable molecular diagnostic results that assist physicians in making timely and accurate treatment decisions to improve patient outcomes and reduce healthcare costs. We welcome Aspire as a shareholder and we are pleased to have this additional means of accessing capital."
Steven G. Martin, Managing Member of Aspire Capital, said, "Liquid biopsy represents a fundamental shift in how cancer patients can be diagnosed and monitored, which we strongly believe will translate into better treatment decisions and outcomes. Biocept is uniquely positioned to capitalize on this opportunity through its capability of assaying both circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA). By validating the high specificity and sensitivity of its assays through collaborations with renowned research institutions and partnering with additional healthcare payers, we believe Biocept is establishing its position as an emerging leader in the field of liquid biopsy. We look forward to developing a long-term relationship and supporting Biocept as it executes on its business plan."
Under the agreement, Aspire has committed to purchase the remaining $14 million if and when Biocept decides to sell shares to Aspire. For this commitment, Biocept has issued 165,000 shares as a commitment fee to Aspire. Aspire has no rights to require any sales of shares at any time. The agreement does not limit Biocept on the use of any of the proceeds. The agreement does not contain any financial covenants, restrictions on future financings, rights of first refusal, participation rights or penalties whatsoever. Biocept can terminate the agreement at any time without any cost or penalty.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. Details of the purchase agreement and registration rights agreement were filed with the SEC on Form 8-K on December 21, 2015.
About Biocept
Biocept, Inc. is a commercial-stage molecular diagnostics company that utilizes a proprietary technology platform and a standard blood sample to provide physicians with important prognostic and predictive information to enhance individual treatment of patients with cancer. Biocept's patented technology platform captures and analyzes circulating tumor DNA, both in CTCs and in plasma (ctDNA). Biocept currently offers assays for gastric cancer, breast cancer, lung cancer, colorectal cancer and melanoma, and plans to introduce CLIA-validated assays for prostate cancer and other solid tumors in the near term. For additional information, please visit www.biocept.com.
About Aspire Capital Fund, LLC
Aspire Capital takes a fundamental investment approach and invests in a wide range of companies and industries emphasizing life sciences, energy and technology.
Forward-Looking Statements
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although Biocept believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, Biocept can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to Biocept's ability to efficiently raise capital from Aspire and effectively minimize dilution to existing shareholders, Biocept's use of the proceeds from the sale of common stock to Aspire, Biocept being able to expand its menu of commercial assays, drive physician adoption and improve the detection and treatment of cancer, and Biocept being able to reduce healthcare costs, enhance individual treatment of patients with cancer and emerge as a leader on the field of liquid biopsy, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in Biocept's SEC filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. Biocept does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law. Readers are advised to review Biocept's filings with the SEC, which can be accessed over the Internet at the SEC's website located at www.sec.gov.
Logo - http://photos.prnewswire.com/prnh/20151013/276540LOGO
With all this great news, you would think this stock would start moving. Just a gut feeling, I think we've reached the bottom.
Nice to see a new post. All I want for Xmas is some really good news. Glta
Just some reading material that came out today. General Cannabis Corporation Up-Listed to OTCQBMay 05, 2015
OTC Disclosure & News Service
-
DENVER, May 5, 2015 (GLOBE NEWSWIRE) -- Advanced Cannabis Solutions, d/b/a General Cannabis Corporation (OTC:CANN), a service provider to businesses in the regulated cannabis industry, today announced that its common stock is being up-listed to the OTCQB effective May 6, 2015.
Robert Frichtel, CEO of General Cannabis, stated, "The Company is extraordinarily excited about this demonstrated improvement in the market categorization of the company as we believe it relates directly to the improvement in our level of financial and corporate disclosure. We have worked toward this for some time now, and this up-listing demonstrates our commitment to building a great company. Our current and future shareholders should all be very pleased with this development. We believe that the up-listing will enhance liquidity and boost our profile, which should benefit everyone who owns ACS stock."
OTCQB companies must be registered with and reporting to the SEC or a U.S. regulatory agency. Approximately 4,000 companies are currently listed on the OTCQB.
The Company plans to build on its successful progression and will continue working towards its goal of meeting the listing requirements for trading on a stock exchange such as the NYSE Euronext or NASDAQ in the future.
About General Cannabis Corporation
General Cannabis Corporation provides services to the regulated cannabis industry throughout the United States. We lease growing space and related facilities (commercial real estate and equipment) to licensed cannabis business operators for their production needs.
Through Iron Protection Group, we provide security services tailored to the cannabis industry including armed guards, cash transport and secure cannabis transport services.
We are pursuing ancillary business products and services including customized finance, capital formation, banking, regulatory compliance consulting, security and advanced logistical support for grow operations.
As previously announced, Advanced Cannabis Solutions, Inc. intends to seek shareholder approval to change its name to General Cannabis Corporation. The Company expects to effect the name change this spring in connection with its annual shareholders' meeting.
www.generalcann.com
Forward Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including the risks identified in the Company's filings with the Securities and Exchange Commission (the "SEC"), including but not limited to Risk Factors contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.
CONTACT: Robert Frichtel CEO GCC, Inc. (303) 759-1300 Or Michael Porter, President Porter LeVay & Rose, Inc. (212) 564-4700 mike@plrinvest.com
Copyright © 2015 GlobeNewswire. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
Thank you. That helps explain why there is now such a small short position. For those that trade smart and shorted this on it's way to $60, because of cnbc's error, and didn't bail before the halt appear to have already reconciled.
I know the website, and the few current short positions left. What I don't understand is if you did short the stock what would your shares be worth today if you didn't sell? I've never shorted a stock that ended up on the grays and returned. Thanks in advance.
Does anyone know how any shorts still holding this stock before halt are handled now that cann is relisted?
Not sure why things didn't blow last week when the news came out. The story in January when they settled there suit against the one investor had a better response. Hoping the volume picks up this week.